Realtime | Geld | Brief | Zeit |
---|---|---|---|
1,600 | 1,750 | 10.10. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
29.09. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT POSITIVE PRELIMINARY RESULTS FROM THE PHASE I MAD STUDY LAE102 DEMONSTRATED ENCOURAGING TREND TOWARDS LEAN BODY ... | 2 | HKEx | ||
17.09. | LAEKNA-B (02105): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
17.09. | LAEKNA-B (02105): COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
10.09. | LAEKNA-B Nosedives 16%+ on 9.5% Discounted Shr Placement to Raise HKD578M Net | 1 | AASTOCKS | ||
10.09. | LAEKNA-B Places Shrs at 9.5% Discount to Raise Net Proceeds of $578M | 1 | AASTOCKS | ||
LAEKNA Aktie jetzt für 0€ handeln | |||||
10.09. | LAEKNA-B (02105): PLACING OF NEW SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
21.08. | LAEKNA-B (02105): INTERIM REPORT 2025 | - | HKEx | ||
13.08. | LAEKNA-B (02105): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 | 1 | HKEx | ||
31.07. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT INVESTIGATIONAL NEW DRUG APPROVAL FOR LAE103 WAS OBTAINED FROM THE U.S. FOOD AND DRUG ADMINISTRATION | 1 | HKEx | ||
29.07. | LAEKNA-B (02105): DATE OF BOARD MEETING | - | HKEx | ||
30.06. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT SUBMISSION OF INVESTIGATIONAL NEW DRUG APPLICATION FOR LAE103 TO THE U.S. FOOD AND DRUG ADMINISTRATION | 2 | HKEx | ||
23.06. | LAEKNA-B (02105): VOLUNTARY ANNOUNCEMENT PRESENTATIONS OF CLINICAL AND PRECLINICAL STUDIES RESULTS OF LAE02, LAE03 AND LAE123 AT 2025 ADA | - | HKEx | ||
03.06. | LAEKNA-B (02105): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 3 JUNE 2025 | - | HKEx | ||
12.05. | LAEKNA-B (02105): PROXY FORM FOR THE ANNUAL GENERAL MEETING | - | HKEx | ||
12.05. | LAEKNA-B (02105): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
12.05. | LAEKNA-B (02105): PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES, RESELL TREASURY SHARES AND REPURCHASE SHARES; PROPOSED RE-ELECTION OF DIRECTORS; ... | - | HKEx | ||
08.05. | LAEKNA-B (02105): GRANT OF RESTRICTED SHARE UNITS | - | HKEx | ||
23.04. | LAEKNA-B (02105): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
23.04. | LAEKNA-B (02105): 2024 ANNUAL REPORT | 1 | HKEx |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 40,470 | -1,56 % | Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In Japan | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 20,050 | -3,19 % | Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 | ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere... ► Artikel lesen | |
EVOTEC | 6,698 | -0,86 % | Adidas, Bechtle, Bitcoin Group, Evotec, Renk, Ströer - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
89BIO | 14,800 | -0,34 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
BIONTECH | 87,95 | -2,66 % | BioNTech Aktie zeigt Stärke: Es wird spannend! | Seit dem letzten 4investors.de-Chartcheck zur BioNTech Aktie hat sich einiges getan. Der Aktienkurs des Mainzer Biotech-Konzerns ist an der NASDAQ um rund 9 Dollar gestiegen, hat die 20- und 50-Tage-Linie... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,305 | -10,16 % | Recursion Pharmaceuticals (RXRX) Climbs 16% Ahead of AI Conference | ||
BEAM THERAPEUTICS | 26,340 | -5,49 % | Jefferies stuft Beam Therapeutics auf "Buy": Kommende Katalysatoren im Fokus | ||
MOONLAKE IMMUNOTHERAPEUTICS | 10,290 | +9,35 % | Oppenheimer senkt Kursziel für Moonlake Immunotherapeutics nach durchwachsenen Studienergebnissen | ||
MINERALYS THERAPEUTICS | 42,170 | +6,95 % | Mineralys Therapeutics: Aktie erreicht Rekordhoch von 41,11 USD | ||
ARCELLX | 86,80 | -1,84 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
LENZ THERAPEUTICS | 38,740 | -16,27 % | Piper Sandler raises LENZ Therapeutics stock price target to $67 on VIZZ launch | ||
APOGEE THERAPEUTICS | 52,45 | -1,43 % | Apogee Therapeutics sichert sich 323,3 Mio. US-Dollar durch Aktienplatzierung an der NASDAQ | ||
BICARA THERAPEUTICS | 17,780 | -2,58 % | Bicara Therapeutics files $400M mixed securities shelf | ||
COGENT BIOSCIENCES | 16,250 | +0,37 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 21,320 | -5,87 % | UBS bestätigt Kaufempfehlung für Summit Therapeutics vor ESMO-Daten |